Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-07-26
2000-01-04
Johnson, Nancy A
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514183, 514908, 540478, 540479, 546 91, A61K 3133, A61K 4342, A61K 31485, C07D51904
Patent
active
060110414
ABSTRACT:
The present invention is particularly directed to the use of a derivative of vinblastine, 3',4'-anhydrovinblastine (AHVB), which differs from vinblastine in that it possesses a double bond at the 3',4' position of the caranthine nucleus rather than the hydroxyl group that is present in the parent structure, as an antineoplastic agent in the therapeutic treatment of cancer. Specifically, the treatment of lymphoma with 3',4'-anhydrovinblastine is disclosed.
REFERENCES:
patent: 4029663 (1977-06-01), Gutowski et al.
patent: 4144237 (1979-03-01), Kutney
patent: 4307100 (1981-12-01), Langlois et al.
Registry No. 38390-45-3, Jun. 26, 1997.
LeChevalier et al, Anticancer Res. vol. 12 p. 1794, 1992.
REmington's Pharmaceutical Sciences, 16 Edition, pp. 1518-1534, 1980.
Kutney James
Mayer Lawrence
Schmidt Bruce
Haile Lisa A.
Johnson Nancy A
University of British Columbia
LandOfFree
Use of anhydrovinblastine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of anhydrovinblastine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of anhydrovinblastine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1072871